A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations
- Author:
Dushyant Singh DAHIYA
1
;
Asim KICHLOO
;
Farah WANI
;
Jagmeet SINGH
;
Dhanshree SOLANKI
;
Hafeez SHAKA
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2022;20(3):342-349
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
Methods:For 2016–2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
Results:We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40–65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
Conclusions:Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.
